High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan

OBJECTIVE To investigate the prevalence and causes of diabetes in patients with primary aldosteronism (PA) in a multi-institutional cohort study in Japan. RESEARCH DESIGN AND METHODS The prevalence of diabetes was determined in 2,210 patients with PA (diagnosed or glycated hemoglobin [HbA1c] ≥6.5% [≥48 mmol/mol]; NGSP) and compared with that of the Japanese general population according to age and sex. In 1,386 patients with PA and clear laterality (unilateral or bilateral), the effects of plasma aldosterone concentration (PAC), hypokalemia (<3.5 mEq/L), suspected subclinical hypercortisolism (SH; serum cortisol ≥1.8 µg/dL after 1-mg dexamethasone suppression test), and PA laterality on the prevalence of diabetes or prediabetes (5.7% ≤ HbA1c <6.5% [39 mmol/mol ≤ HbA1c <48 mmol/mol]) were examined. RESULTS Of the 2,210 patients with PA, 477 (21.6%) had diabetes. This prevalence is higher than that in the general population (12.1%) or in 10-year cohorts aged 30–69 years. Logistic regression or χ2 test revealed a significant contribution of suspected SH to diabetes. Despite more active PA profiles (e.g., higher PAC and lower potassium concentrations) in unilateral than bilateral PA, BMI and HbA1c values were significantly higher in bilateral PA. PA laterality had no effect on the prevalence of diabetes; however, the prevalence of prediabetes was significantly higher in bilateral than unilateral PA. CONCLUSIONS Individuals with PA have a high prevalence of diabetes, which is associated mainly with SH. The prevalence of prediabetes is greater for bilateral than unilateral PA, suggesting a unique metabolic cause of bilateral PA.

[1]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[2]  Katsutoshi Takahashi,et al.  Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. , 2011, Endocrine journal.

[3]  F. Turchi,et al.  Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study , 2007, Journal of hypertension.

[4]  Yunxia Zhu,et al.  Aldosterone induces clonal β-cell failure through glucocorticoid receptor , 2015, Scientific Reports.

[5]  J. M. Luther Effects of aldosterone on insulin sensitivity and secretion , 2014, Steroids.

[6]  G. Bakris,et al.  Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review , 2006, Hypertension.

[7]  L. Sechi,et al.  Insulin sensitivity in patients with primary aldosteronism: a follow-up study. , 2006, The Journal of clinical endocrinology and metabolism.

[8]  T. Fukuoka,et al.  Optimum position of left adrenal vein sampling for subtype diagnosis in primary aldosteronism , 2015, Clinical endocrinology.

[9]  X. Jeunemaître,et al.  Fasting Plasma Glucose and Serum Lipids in Patients With Primary Aldosteronism: A Controlled Cross-Sectional Study , 2009, Hypertension.

[10]  D. Schteingart Role for Adrenal Venous Sampling in Primary AldosteronismYoung WF Jr, Stanson AW, Thompson GB, et al (Mayo Clinic, Rochester, Minn) Surgery 136:1227–1235, 2004§ , 2006 .

[11]  D. Jacobs,et al.  Plasma Aldosterone Levels and Development of Insulin Resistance: Prospective Study in a General Population , 2011, Hypertension.

[12]  T. Yoshimoto,et al.  Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome. , 2011, Endocrine journal.

[13]  K. Okada,et al.  High normal blood pressure, hypertension, and the risk of type 2 diabetes in Japanese men. The Osaka Health Survey. , 1999, Diabetes care.

[14]  J. Ceral,et al.  Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results , 2010, European journal of endocrinology.

[15]  Katsutoshi Takahashi,et al.  Significance of Computed Tomography and Serum Potassium in Predicting Subtype Diagnosis of Primary Aldosteronism , 2018, The Journal of clinical endocrinology and metabolism.

[16]  Yutaka Imai,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014) , 2014, Hypertension Research.

[17]  M. Ermani,et al.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  Tomoaki Tanaka,et al.  New diagnostic criteria of adrenal subclinical Cushing's syndrome: opinion from the Japan Endocrine Society. , 2018, Endocrine journal.

[19]  W. Scherbaum,et al.  Human adipocytes secrete mineralocorticoid-releasing factors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Yen-Hung Lin,et al.  Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years , 2017, Journal of hypertension.

[21]  Hyun-Young Park,et al.  Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study , 2015, Hypertension Research.

[22]  J. Conn,et al.  CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES. , 1964, American journal of surgery.

[23]  P. Gorden Glucose Intolerance with Hypokalemia: Failure of Short-term Potassium Depletion in Normal Subjects to Reproduce the Glucose and Insulin Abnormalities of Clinical Hypokalemia , 1973, Diabetes.

[24]  D. Rizzoni,et al.  Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. , 2008, The Journal of clinical endocrinology and metabolism.

[25]  Michael Biehl,et al.  Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism , 2017, JCI insight.

[26]  M. Litwin,et al.  Guidelines for the Management of Hypertension , 2015 .

[27]  A. Richards,et al.  Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. , 2003, The Journal of clinical endocrinology and metabolism.

[28]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[29]  H. Sasano,et al.  Primary aldosteronism associated with subclinical Cushing syndrome , 2012, Journal of Endocrinological Investigation.

[30]  N. Sattar,et al.  High Blood Pressure and Its Association With Incident Diabetes Over 10 Years in the Korean Genome and Epidemiology Study (KoGES) , 2015, Diabetes Care.

[31]  W. Haynes,et al.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications , 2012, Hypertension Research.

[32]  B. Biondi,et al.  Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. , 2002, The Journal of clinical endocrinology and metabolism.

[33]  S. Bornstein,et al.  Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II — sensitization in human adrenocortical cells , 2007, International Journal of Obesity.

[34]  H. Itoh,et al.  Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. , 2012, American journal of hypertension.

[35]  Classi fi cation and Diagnosis of Diabetes : Standards of Medical Care in Diabetes d 2019 , 2018 .

[36]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[37]  P. Hopkins,et al.  Aldosterone production and insulin resistance in healthy adults. , 2010, The Journal of clinical endocrinology and metabolism.